2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1109

Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Abstract Number: 1758

Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Abstract Number: 2217

DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids
Abstract Number: 718

Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions
Abstract Number: 832

Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria
Abstract Number: 2127

Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Abstract Number: 723

Diagnosis of Systemic Sclerosis: How and When
Abstract Number: 633

Diagnostic Delay in Spondyloarthritis
Abstract Number: 491

Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis
Abstract Number: 559

Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Abstract Number: 193

Diet as a Risk Factor for Rheumatoid Arthritis
Abstract Number: 829

Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia
Abstract Number: 2927

Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 89

Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Abstract Number: 2482

Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].